Combining Cancer Immunotherapies

Targeted therapies act by blocking essential biochemical pathways or mutant proteins that are required for tumor cell growth and survival. These drugs can arrest tumor progression and induce striking regressions in molecularly defined subsets of patients. Indeed, the first small molecule targeted agent, the BCR-ABL kinase inhibitor imatinib, rapidly induced complete cytogenetic responses in 76% of chronic myelogenous leukemia patients. Further research into the underlying genetic pathways driving tumor proliferation uncovered additional oncoproteins that are critical for tumor maintenance, such as the epidermal growth factor receptor (EGFR), BRAF, KIT, HER (also known as neu and ERBB) and anaplastic lymphoma kinase (ALK). Similar to imatinib, small molecule inhibitors of these kinases have effectuated impressive tumor responses in selected patients, although regressions are commonly followed by the development of progressive disease due to the emergence of drug-resistant variants. Resistance usually involves secondary mutations within the targeted protein or compensatory changes within the targeted pathway that bypass the drug-mediated inhibition. Accordingly, targeted therapies may elicit dramatic tumor regressions, but persistence is generally short-lived, limiting the overall clinical benefit.

  • Targeted therapies
  • Rationale for immunotherapy
  • Combining radiotherapy
  • Standard therapies
  • Androgen manipulation
  • T-cell modulation
  • Inter-Leukeins
  • Interferons
  • T- cell growth
  • Cell Proliferation

Related Conference of Combining Cancer Immunotherapies

November 06-07, 2017

2nd International Conference on Autoimmunity

Frankfurt, Germany
November 08-09, 2017

3rd Antibodies and Bio Therapeutics Congress & B2B

Las Vegas, Nevada, USA
November 13-14, 2017

5th International Conference on HIV/AIDS, STDs and STIs

Las Vegas, Nevada, USA
Dec 14-15, 2017

World Immunology Congress

Dubai, UAE
May 28-29, 2018

World Congress on Allergy and Immunotherapy

Osaka, Japan

9th European Immunology Conference

June 14-16, 2018 Rome, Italy
July 12-13, 2018

5th International Conference on Parasitology

Paris, France

Combining Cancer Immunotherapies Conference Speakers

Recommended Sessions

Related Journals

Are you interested in